CASP3 gene and breast cancer treatment resistance

This study looks at how genetic differences in Egyptian people with breast or colorectal cancer might affect the side effects of the chemotherapy drug capecitabine. The goal is to understand why some people have more side effects than others.

This study looks at which DNA “repair” gene changes are found in breast cancer patients, especially certain subtypes and high-risk situations. Your genetic test results may help researchers understand who has specific DNA repair pathway mutations and how they relate to breast cancer.

This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.

This study looks at specific molecules in the body that can change how your genes work (epigenetic mediators) in women who have just been diagnosed with breast cancer. The goal is to understand these markers better, which could help improve treatment in the future.

This study looks at the genetic and protein markers of early breast cancer in Pakistani women. It aims to understand the disease better and possibly guide future treatments.

This trial tests new treatment given before surgery for certain stage IIb–IIIc breast cancers. It uses results from your tumor to guide the treatment plan and aims to improve how well the therapy works before the operation.